TOP > 外国特許検索 > POLYMERIZED PEPTIDE AND GEL HAVING COLLAGEN-LIKE STRUCTURE

POLYMERIZED PEPTIDE AND GEL HAVING COLLAGEN-LIKE STRUCTURE UPDATE

外国特許コード F170008954
整理番号 (S2015-1677-N0)
掲載日 2017年2月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP068667
国際公開番号 WO 2016208673
国際出願日 平成28年6月23日(2016.6.23)
国際公開日 平成28年12月29日(2016.12.29)
優先権データ
  • 特願2015-127450 (2015.6.25) JP
発明の名称 (英語) POLYMERIZED PEPTIDE AND GEL HAVING COLLAGEN-LIKE STRUCTURE UPDATE
発明の概要(英語) Although collagen is useful as a medicinal material, its use in humans involves the risks of allergy and zoonoses. Therefore, artificial collagens and the like are being studied as medicinal materials. However, typical artificial collagens cannot be considered completely sufficient, given their lack of physical strength, being denatured by heat, inability to be processed into a sheet, and the like, and thus being problematic in terms of practicality. In the present invention, a collagen-like peptide having a triple helical structure comprising triple strands of peptide chains including a plurality of cysteine (cys) residues is oxidized and cross-linked to prepare a polymerized peptide. This polymerized peptide may be processed into and used as a hydrogel and a thin-film sheet. In addition, by inserting a functional amino acid sequence present in biomacromolecules, particular physiological functions such as cell adhesiveness may be obtained. Further, the present invention provides: methods for preparing the polymerized peptide and the like; and uses thereof as compositions in cell cultures, wound coverings, regenerative medicinal materials, and research materials and the like by using the same.
従来技術、競合技術の概要(英語) BACKGROUND ART
Collagen, (Xaa-Yaa-Gly) - - composed of repetition of the basic unit of a peptide having the amino acid sequence of the primary structure (Xaa and Yaa is any amino acid residues of) 3 of the strand, triple-helical structures of proteins that form a collective term for the, among the cells present in the tissue of the animal which are major constituents of the extracellular matrix. Rich animal connective tissue, constituting the skeleton structure of the tissue. 28 Human collagen protein is reported to be one. On the other hand, the primary structure motif in the amino acid sequence has a built-in with biological activity, for example, the tissue in the wound tissue damage such as to be exposed to the blood by collagen, glycoprotein VI (GPVI) receptor and integrin α 2 β 1 receptors binding to blood platelets in the wound site as a trigger causing activation of a blood coagulation system, such as having the activity of promoting wound healing and hemostasia (non-patent document 1).
Therefore, the use of the strength and the physiological activity of a collagen, such as the livestock or fish collagen with water collected from the extracted gelatin produced by a method including heating, applied to stop bleeding or decubitus ulcers pharmaceutical product and medical material, the raw material of the capsules and the like, further a cosmetic raw material and the food material has been widely used as.
However, in common with the collected collagen infect livestock human prion diseases such as for example the development of admission, in order to ensure the safety of the collagen from livestock supply is regulated, in the industrial field associated with the supply of the collagen to become unstable.
In addition, the native collagen, such as through the integrin receptor α 2 β 1 as well as effects on platelets, discoidin receptor, syndecan receptor and fibronectin to a cell having a variety of substrates such as adhesive (non-patent document 1) have activity. Therefore, the natural collagen, selectively energizing the physiological activities of the desired collagen having acquired and utilized it is substantially difficult.
Therefore, paying attention to these properties of collagen, collagen-like structures and a collagen-like peptide having an activity to produce a non-naturally occurring, application to medical materials or study materials has been attempted (patent document 1, 2).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • WASEDA UNIVERSITY
  • KOLA-GEN PHARMA INC.
  • 発明者(英語)
  • Hiroshi Nose
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
技術導入、技術提携、実用化開発(受託研究・共同研究等)のご相談を承っております。お気軽にご連絡ください。

PAGE TOP

close
close
close
close
close
close